Virginia Retirement Systems ET AL increased its position in Chemed Co. (NYSE:CHE) by 18.1% in the third quarter, Holdings Channel reports. The institutional investor owned 91,400 shares of the company’s stock after buying an additional 14,000 shares during the quarter. Virginia Retirement Systems ET AL’s holdings in Chemed were worth $29,210,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in CHE. Fort L.P. bought a new stake in Chemed in the 2nd quarter worth approximately $120,000. Cerebellum GP LLC bought a new stake in Chemed in the 3rd quarter worth approximately $148,000. Tower Research Capital LLC TRC lifted its position in Chemed by 70.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 544 shares of the company’s stock worth $175,000 after buying an additional 224 shares during the last quarter. We Are One Seven LLC bought a new stake in Chemed in the 3rd quarter worth approximately $228,000. Finally, Hollencrest Capital Management bought a new stake in Chemed in the 3rd quarter worth approximately $231,000. Institutional investors own 90.39% of the company’s stock.
Shares of CHE stock opened at $312.70 on Tuesday. The company has a quick ratio of 1.11, a current ratio of 1.14 and a debt-to-equity ratio of 0.23. Chemed Co. has a fifty-two week low of $227.14 and a fifty-two week high of $335.99. The company has a market capitalization of $4.94 billion, a price-to-earnings ratio of 58.34, a P/E/G ratio of 2.69 and a beta of 1.23.
Chemed (NYSE:CHE) last announced its quarterly earnings data on Monday, October 29th. The company reported $3.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.80 by $0.27. Chemed had a return on equity of 35.13% and a net margin of 11.73%. The firm had revenue of $444.15 million during the quarter, compared to the consensus estimate of $445.16 million. During the same quarter in the previous year, the company posted $2.15 earnings per share. The business’s revenue was up 6.4% on a year-over-year basis. On average, equities analysts predict that Chemed Co. will post 11.41 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Monday, November 12th will be given a $0.30 dividend. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.20 annualized dividend and a yield of 0.38%. Chemed’s payout ratio is currently 22.39%.
A number of research firms recently weighed in on CHE. Bank of America began coverage on Chemed in a research report on Friday, October 12th. They issued a “buy” rating and a $390.00 target price for the company. ValuEngine downgraded Chemed from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Tuesday, September 25th. Finally, Royal Bank of Canada boosted their price objective on Chemed to $321.00 and gave the company a “market perform” rating in a research report on Monday, July 30th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $334.00.
In other Chemed news, Director Donald E. Saunders sold 300 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $319.22, for a total value of $95,766.00. Following the completion of the sale, the director now owns 8,701 shares in the company, valued at $2,777,533.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin J. Mcnamara sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, August 23rd. The shares were sold at an average price of $319.50, for a total value of $1,278,000.00. Following the completion of the sale, the insider now owns 139,491 shares of the company’s stock, valued at approximately $44,567,374.50. The disclosure for this sale can be found here. Insiders sold 13,006 shares of company stock valued at $4,064,958 in the last quarter. Corporate insiders own 4.82% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/11/06/virginia-retirement-systems-et-al-purchases-14000-shares-of-chemed-co-che.html.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Article: What does cost of debt say about a company’s financial health?
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.